

Atty Docket No. P29875

Application No. 10/577,343

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Yasuharu NISHIMURA et al.

Confirmation No.: 4864

Appln. No. : 10/577,343

Group Art Unit: 1645

Filed : March 5, 2007

Examiner: Not Yet Assigned

For : DIAGNOSTIC AGENT FOR MALIGNANT MELANOMA

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop _____
Randolph Building
401 Dulany Street
Alexandria VA 22314

Sir:

Further to the Information Disclosure Statement filed November 13, 2007, and in accordance with the duty of disclosure under 37 C.F.R. 1.56, 1.97, and 1.98, Applicants hereby call to the Office's attention the following information, which includes documents cited in a Supplementary European Search Report dated July 26, 2007, issued in connection with corresponding European Application No. EP 04 79 3354:

NAKATSURA et al., "Identification of Glypican-3 as a Novel Tumor Marker for Melanoma," Clinical Cancer Research, Vol. 10, No. 19, pages 6612-6621 (2004);

SAIKALI et al., "Expression of glypican 3(GPC3) in embryonal tumors," International Journal of Cancer, Vol. 89, No. 5, pages 418-422 (2000); and

CAPPURO et al., "Overexpression of glypican-3 human hepatocellular carcinomas determined by immunohistochemistry using a monoclonal antibody," Proceedings of the Annual Meeting of the American Association for Cancer Research, Vol. 43, page 219 (2002).


Copies of the above-listed documents and the Supplementary Search Report for European Application No. 04 79 3354 are enclosed together with a completed copy of the PTO-1449 Form listing these documents. Accordingly, the Examiner is requested to consider these documents and to indicate such consideration by returning a signed and initialed copy of the PTO-1449 Form with the next official communication.

Applicants note that while this Supplemental Information Disclosure Statement is being filed more than three months from the filing date, Applicants have not received an action on the merits from the U.S. Patent and Trademark Office. Accordingly, consideration of the enclosed documents are required under 37 C.F.R. 1.97(b)(3).

However, if an action on the merits has been mailed prior to the filing date of this Supplemental Information Disclosure Statement, Applicants hereby authorize the charging of any required fees necessary for consideration of the documents cited herein to Deposit Account No. 19-0089.

If there should be any questions, the Examiner is invited to contact the undersigned at the telephone number listed below.

Respectfully submitted,
Yasuharu NISHIMURA


Bruce H. Bernstein
Reg. No. 29,027
42,920

November 30, 2007
GREENBLUM & BERNSTEIN, P.L.C.
1950 Roland Clarke Place
Reston, VA 20191
(703) 716-1191